

Testing the association between blood type and COVID-19 infection, intubation, and death

This manuscript ([permalink](#)) was automatically generated from [zietzm/abo_covid@82c9fbc](#) on April 6, 2020.

Authors

- **Michael Zietz**

 [0000-0003-0539-630X](#) ·  [zietzm](#) ·  [ZietzMichael](#)

Department of Biomedical Informatics, Columbia University · Funded by NIH T15 LM007079

Abstract

The rapid global spread of the novel coronavirus SARS-CoV-2 has strained existing healthcare and testing resources, making the identification and prioritization of individuals most at-risk a critical challenge. A recent study of patients in China discovered an association between ABO blood type and SARS-CoV-2 infection status by comparing COVID-19 patients with the general population. Whether blood type is associated with increased COVID-19 morbidity or mortality remains unknown. We used observational healthcare data on 1559 COVID-tested individuals (682 COV+) with known blood type in the New York Presbyterian (NYP) hospital system to assess the association between ABO+Rh blood type and SARS-CoV-2 infection status, intubation, and death. A higher proportion of blood group A and a lower proportion of blood group O were found among COVID-19 patients compared to those testing negative for the virus, though in both cases the result is significant only in Rh positive blood types. A meta-analysis of NYP data with previously reported data from China uncovered significantly increased A and B and significantly decreased O blood groups among COVID-19 patients. Our data do not provide strong evidence of associations between blood group and intubation or death among COVID-19 patients. While our results are based on preliminary observational data collected during the care of patients and should not be used to guide clinical practice, we find further evidence of recently-discovered associations between blood group and SARS-CoV-2 infection status and new evidence of associations between B and Rh blood groups and COVID-19.

Background

The novel Coronavirus disease (COVID-19) has rapidly spread across the globe and has caused over 1,130,000 confirmed infections and over 62,000 deaths worldwide as of April 5, 2020 [1]. A number of risk factors for COVID-19 infection, morbidity, and mortality are known, including age, sex, and a number of chronic conditions and laboratory findings [2]. Recently, a study on COVID-19 patients in Wuhan and Shenzhen, China discovered associations between ABO blood types and infection [3]. Their analysis compared blood groups between hospitalized COVID-19 patients and the general populations of Wuhan and Shenzhen City, as assessed by previously-published samples of healthy individuals. They found that the odds of testing positive for COVID-19 among A blood groups was increased and among O blood groups was decreased relative to the general population. Similarly, previous work has identified associations between ABO blood groups and a number of different infections or disease severity following infections, including SARS-CoV-1 [4], *P. falciparum* [5], *H. pylori* [6], Norwalk virus [7], hepatitis B virus [8], and *N. gonorrhoeae* [9].

Within the United States, New York City has become a major center of the pandemic, with over 64,000 cases and over 2,400 deaths as of April 5, 2020 [10]. We sought to replicate and extend the previous investigation into the association between COVID-19 and blood type using electronic health record data from the New York Presbyterian (NYP) hospital system in New York, USA. We compared both ABO and ABO+Rh blood types, and we investigated three COVID-19 outcomes: infection status, intubation, and death.

Methods

We compared several combinations of blood group definitions (ABO vs ABO+Rh) and COVID-19 outcomes. Outcomes were compared between four pairs of populations: COV+ vs COV-, COV+ vs general population (excluding those tested for COVID-19), COV+/Intubated vs COV+/Not intubated, and COV+/Deceased vs COV+/Alive. For each of the eight test conditions (2 blood group definitions and 4 outcome comparison population pairs), we performed a Pearson's Chi-squared test to test whether blood group distributions differ between the compared populations. Additionally, we compared each blood group against all others using a 2x2 contingency table to determine effect sizes

for each blood group itself. For the one-vs-rest blood group comparisons, we report odds ratios (OR), p-values from Fisher's exact test (two-sided), and odds ratio confidence intervals.

We also performed a meta-analysis using our data in combination with data from Wuhan and Shenzhen reported by Zhao et al. [3]. These analyses used a random effects model to create pooled estimates of odds ratios for each ABO blood group in comparisons between COV+ individuals and the general populations of New York, Wuhan, and Shenzhen.

Individuals with a single positive COVID-19 test were considered COVID+, even if they had previous or subsequent negative COVID tests. Blood group was identified using either a measurement of LOINC code 34474-7, "ABO and Rh group [Type] in Cord blood," or the results of a procedure identified by one of the names listed in Table 4. We excluded individuals with multiple contradictory blood group measurements. The distribution of blood groups in the general population was estimated using blood group lab results on 108,929 individuals recorded in the NYP electronic health record (EHR) system between May 2011 and June 2019, excluding results for any individuals later tested for COVID-19 (regardless of result).

We considered EHR data up to April 5, 2020. Our analyses were conducted using the R language, and we used the `meta` package [11] for meta-analysis. While our data from NYP are protected by HIPAA and cannot be released, we have made all code used for our analysis available at https://github.com/zietzm/abo_covid_analysis. The manuscript was written [openly on GitHub](#) using the Manubot software [12].

Results

We first determined blood groups for COVID-tested individuals using laboratory measurements recorded in the NYP EHR system. One individual with multiple contradictory blood group measurements was excluded, resulting in 1,559 individuals with known blood groups who received a COVID-19 test (either positive or negative result). Of these, 682 were COV+ (positive in at least one COVID-19 test) and 877 were COV- (negative in all COVID-19 tests administered). Among the COV+ individuals, 179 were intubated and 80 had died, while the remaining individuals had not been intubated and remained alive as of April 5, 2020. We found that 354 tested COV- individuals were intubated during the same time, though we did not include them in any analysis.

For each comparison cohort pair, we performed chi-squared tests using both ABO and ABO+Rh blood types (Tables 1, 5). Since there were no AB-negative individuals testing positive for COVID-19 and only 5 individuals testing negative, we excluded AB-negative from all ABO+Rh analyses. Finally, we conducted individual tests of each blood type against all others (within the same ABO vs ABO+Rh system) for each of the COVID-19 outcomes we considered (Full data in Table 6).

We found associations between COVID-19 status and both ABO ($p=0.006$) and ABO+Rh ($p=0.031$) blood groups in a comparison between individuals testing positive vs testing negative (Tables 1, 2). Blood groups A were associated with increased odds of testing positive for COVID-19 (OR 1.338, $p=0.009$), while O blood groups were associated with decreased odds of testing positive (OR 0.790, $p=0.036$). While few individuals with AB blood groups were included (21 COV+, 47 COV-), we also found AB blood groups to be associated with decreased odds of testing positive (OR 0.561, $p=0.033$). When we tested individual ABO+Rh blood groups against all others, we discovered that strong associations are only found in Rh positive blood groups (Tables 2, 6). Finally, we compared the blood group distributions between all individuals tested for COVID-19 with the general population at NYP, finding insufficient evidence to conclude that tested individuals are not drawn from the general population at random (Chi-squared 3.8896, $p=0.2736$).

Table 1: Summary of chi-squared tests for association between blood type and COVID-19 outcomes. "df" indicates the

degrees of freedom; ABO used a 4x2 table for each test, while ABO+Rh used a 6x2 table for each test, resulting in 3 and 5 degrees of freedom, respectively.

Blood group type	Comparison groups	Chi-squared	df	p-value
ABO	COV+ vs general population	5.288	3	0.152
ABO+Rh	COV+ vs general population	9.129	6	0.166
ABO	COV+ vs COV-	12.295	3	0.006
ABO+Rh	COV+ vs COV-	13.882	6	0.031
ABO	COV+/Intubated vs COV+/Not intubated	3.493	3	0.322
ABO+Rh	COV+/Intubated vs COV+/Not intubated	5.844	6	0.441
ABO	COV+/Died vs COV+/Alive	3.190	3	0.363
ABO+Rh	COV+/Died vs COV+/Alive	7.431	6	0.283

Table 2: Summary of one-vs-rest analysis for a comparison of COV+ vs COV- individuals. Each test compares the listed blood group to all other blood groups (combined) between the COV+ and COV- individuals. OR means odds ratio (COV+ vs COV-), and the 95% CI is a confidence interval on the OR. P-values computed using Fisher's exact test.

Blood group	Blood group type	OR	95% CI	p-value
A	ABO	1.338	1.072 - 1.672	0.009
A-negative	ABO+Rh	0.832	0.42 - 1.608	0.641
A-positive	ABO+Rh	1.382	1.099 - 1.737	0.004
AB	ABO	0.561	0.315 - 0.969	0.033
AB-positive	ABO+Rh	0.628	0.35 - 1.097	0.093
B	ABO	1.117	0.843 - 1.477	0.446
B-negative	ABO+Rh	0.636	0.216 - 1.695	0.381
B-positive	ABO+Rh	1.169	0.874 - 1.563	0.282
O	ABO	0.804	0.654 - 0.987	0.036
O-negative	ABO+Rh	1.034	0.548 - 1.93	1.000
O-positive	ABO+Rh	0.790	0.642 - 0.971	0.024

Meta-analysis

Finally, we compared our data from New York City to the data from Wuhan and Shenzhen presented by Zhao et al. [3] and conducted a meta-analysis using the data they report in combination with our NYP data. Zhao et al. used a random effects model to meta-analyze data between three different hospitals (Wuhan Jinyintan, Renmin Hospital in Wuhan, and Shenzhen Third People's Hospital), comparing each hospital's COV+ blood group distribution to the general population distribution for each city. We performed a similar analysis—including NYP data—to assess the effect of blood type in the combined data from all four sources (full counts in Table 7).

We found that the distribution of blood groups in the general population at NYP differs significantly from both the distributions in Shenzhen (Chi-squared = 2056, p-value < 2.2e-16) and Wuhan (Chi-squared = 583.29, p-value < 2.2e-16) (Table 7). The difference in distributions is reflected in tests of heterogeneity between sites, where we find more heterogeneity between sites in our meta-analysis than Zhao et al.'s meta-analysis (Table 9).

We fit a random effects model for each ABO blood type using data from NYP and the three sources for which Zhao et al. report data. The overall associations between ABO blood groups and COVID-19 status that Zhao et al. identified (significantly increased COV+ odds for blood group A and decreased COV+ odds for blood group O) are replicated in our meta-analysis (Table 3). Using the additional data from NYP, the pooled association between blood group B becomes larger in effect size and significant at the 5% level (original: OR 1.09, $p=0.121$; with NYP data: OR 1.25, $p=0.0361$).

Table 3: Meta-analysis associations for individual ABO blood groups in comparisons of COV+ vs general population using a random effects model. Each blood group was compared against all others using data from NYP, and Zhao et al. (Wuhan Jinyintan, Renmin Hospital in Wuhan, and Shenzhen Third People's Hospital). OR refers to the pooled odds ratio (COV+ vs general population), and the 95% CI is a confidence interval on the OR. P-values are for the pooled association from the random effects model.

Blood group	OR	95% CI	p-value
A	1.1636	1.0155 - 1.3333	0.0291
B	1.1101	1.0068 - 1.2240	0.0361
AB	1.2519	0.8384 - 1.8694	0.2721
O	0.7252	0.5971 - 0.8807	0.0012

Discussion

We stratified by ABO+Rh blood groups in a comparison of COV+ vs COV- individuals and found that A and O associations were only supported by evidence among those with Rh positive blood groups. Negative Rh blood groups are less common in our data, representing only 9.25% of individuals, so the lack of evidence for association with negative blood types could be due to lower sample sizes. However, odds ratios for ABO groups A and O are less extreme than the associated ABO+Rh blood groups (A+, O+), and the corresponding negative blood groups (A-, O-) have (insignificant) odds in the opposite directions as their positive counterparts. Further work is needed to better understand the associations between Rh negative blood groups and COVID-19.

Our meta-analysis found large heterogeneity in blood group distributions between Wuhan, Shenzhen, and New York City, consistent with previous work indicating large differences in blood group distributions between the United States and China [13,14]. Overall blood group differences introduced heterogeneity in our meta-analysis comparisons of blood group between COV+ individuals and the general population. Larger sample sizes of COVID-19 patients will allow afford a more detailed picture of the effects of blood type on COVID-19 susceptibility.

The significant associations we found for blood type between COV+ and COV- individuals were far from significant in a comparison between COV+ and the general population at NYP. A possible explanation for this finding is that individuals tested for infection at NYP represent a more homogeneous sub-population of patients at NYP. Increased homogeneity would strengthen the blood-group-COVID-19 association signal as it would reduce the influence of overall population differences in blood-type distribution. We did not find sufficient evidence to conclude that COVID-19-tested individuals have a significantly different blood group distribution than the general population at NYP, though we cannot rule out other differences between tested and general populations that could explain the difference in associations. Moreover, our meta-analysis using COV+ vs general population found significant associations between A, B, and O blood groups, and the NYP data received 20-30 percent weight for each comparison, indicating a large contribution to the pooled associations. Further work is needed to understand how the population of COVID-tested patients differs from the general population.

We did not identify any significant relationships between blood group and intubation or death due to COVID-19. However, intubation and death due to COVID-19 continue in New York as of April 5, 2020, and individuals currently alive, not intubated, or COV- may reach these outcomes in the future. Our data is preliminary and represents a snapshot of the pandemic in a New York hospital system. When more patients are tested, intubated, and recover, we will be better able to assess the relationship between blood group and eventual COVID-19 outcomes that may not have occurred at the time of our analysis.

Our study was conducted on EHR data collected during the care of patients, not necessarily with research intent. Our sample sizes were relatively small, making stratifications by age, sex, comorbidities, or other risk factors challenging. As an observational study without rigorous corrections for possible confounding, our results should be considered preliminary and should not be taken to inform clinical practice or policy.

Conclusion

In this study we found further evidence for the association between blood group and COVID-19. Using data from NYP, we found the odds of COVID-19 positive vs negative test results were increased in blood groups A and decreased in blood group O, consistent with previous results from Wuhan and Shenzhen [3]. While few individuals were included in our cohort, we discovered a new significant odds decrease for AB blood group. In a meta-analysis of our data with data from Wuhan and Shenzhen reported by Zhao et al., we found significant associations between A, B, and O blood groups and COVID-19. Specifically, we found that A and B blood groups are associated with increased odds and O is associated with decreased odds in a comparison between COV+ and the general population. Our meta-analysis extended previous work using additional data and allowed us to declare significant at the 5% level an association between B blood group and COVID-19 (OR 1.11) that was weaker in the previous study (OR 1.09, $p=0.121$).

Supplemental information

Table 4: Procedures used by name to identify individual blood group

Procedure name
TYPE AND SCREEN
BLOOD TYPE ABO AND RH
TYPE (ABO CONFIRMATION ONLY)
NEWBORN PANEL (ABO/RH PLUS DAT PLUS AB SCREEN)
CORD BLOOD PANEL (ABO/RH PLUS DAT)
NEWBORN BLOOD TYPE

Table 5: Counts of individuals by blood group and the three COVID-19 outcomes assessed (test result, intubation, death), and blood groups estimated for the general population using data from 108,929 individuals not tested for COVID-19.

Blood group	COV+	COV-	COV+/Intubated	COV+/Not intubated	COV+/Died	COV+/Alive	General population
A	233	245	62	171	27	206	35643
A-negative	17	26	2	15	1	16	3447
A-positive	216	219	60	156	26	190	32196

Blood group	COV+	COV-	COV+/Intubated	COV+/Not intubated	COV+/Died	COV+/Alive	General population
AB	21	47	8	13	5	16	4582
AB-negative*	0	5	0	0	0	0	394
AB-positive	21	42	8	13	5	16	4188
B	116	136	35	81	12	104	16229
B-negative	7	14	2	5	0	7	1422
B-positive	109	122	33	76	12	97	14807
O	312	449	74	238	36	276	52406
O-negative	21	26	4	17	0	21	4808
O-positive	291	423	70	221	36	255	47598
Total	682	877	179	503	80	602	108860

* AB-negative was not included in the ABO+Rh analyses as no individuals with that blood type recorded tested positive for COVID-19.

Table 6: Summary of all one-vs-rest analyses conducted. Each individual test compared the listed blood group with all other blood groups between the listed comparison groups. Shown are comparisons between each blood type and all three COVID-19 outcomes investigated.

Blood group	Blood group type	Comparison groups	OR	95% CI	p-value
A	ABO	COV+ vs general population	1.06 ₆	0.906 - 1.252	0.437
A-negative	ABO+Rh	COV+ vs general population	0.77 ₉	0.45 - 1.258	0.379
A-positive	ABO+Rh	COV+ vs general population	1.09 ₈	0.93 - 1.294	0.257
AB	ABO	COV+ vs general population	0.72 ₃	0.444 - 1.116	0.151
AB-positive	ABO+Rh	COV+ vs general population	0.79 ₁	0.486 - 1.221	0.368
B	ABO	COV+ vs general population	1.17 ₀	0.949 - 1.432	0.131
B-negative	ABO+Rh	COV+ vs general population	0.78 ₁	0.312 - 1.622	0.733
B-positive	ABO+Rh	COV+ vs general population	1.20 ₃	0.971 - 1.48	0.083
O	ABO	COV+ vs general population	0.90 ₈	0.778 - 1.059	0.219
O-negative	ABO+Rh	COV+ vs general population	0.68 ₅	0.421 - 1.057	0.092
O-positive	ABO+Rh	COV+ vs general population	0.95 ₂	0.815 - 1.111	0.536
A	ABO	COV+ vs COV-	1.33 ₈	1.072 - 1.672	0.009

Blood group	Blood group type	Comparison groups	OR	95% CI	p-value
A-negative	ABO+Rh	COV+ vs COV-	0.83 2	0.42 - 1.608	0.641
A-positive	ABO+Rh	COV+ vs COV-	1.38 2	1.099 - 1.737	0.004
AB	ABO	COV+ vs COV-	0.56 1	0.315 - 0.969	0.033
AB-positive	ABO+Rh	COV+ vs COV-	0.62 8	0.35 - 1.097	0.093
B	ABO	COV+ vs COV-	1.11 7	0.843 - 1.477	0.446
B-negative	ABO+Rh	COV+ vs COV-	0.63 6	0.216 - 1.695	0.381
B-positive	ABO+Rh	COV+ vs COV-	1.16 9	0.874 - 1.563	0.282
O	ABO	COV+ vs COV-	0.80 4	0.654 - 0.987	0.036
O-negative	ABO+Rh	COV+ vs COV-	1.03 4	0.548 - 1.93	1.000
O-positive	ABO+Rh	COV+ vs COV-	0.79 0	0.642 - 0.971	0.024
A	ABO	COV+/Intubated vs COV+/Not intubated	1.02 9	0.705 - 1.493	0.927
A-negative	ABO+Rh	COV+/Intubated vs COV+/Not intubated	0.36 8	0.04 - 1.608	0.263
A-positive	ABO+Rh	COV+/Intubated vs COV+/Not intubated	1.12 1	0.765 - 1.635	0.575
AB	ABO	COV+/Intubated vs COV+/Not intubated	1.76 2	0.622 - 4.678	0.214
AB-positive	ABO+Rh	COV+/Intubated vs COV+/Not intubated	1.76 2	0.622 - 4.678	0.214
B	ABO	COV+/Intubated vs COV+/Not intubated	1.26 6	0.79 - 1.999	0.298
B-negative	ABO+Rh	COV+/Intubated vs COV+/Not intubated	1.12 5	0.106 - 6.948	1.000
B-positive	ABO+Rh	COV+/Intubated vs COV+/Not intubated	1.26 9	0.783 - 2.027	0.342
O	ABO	COV+/Intubated vs COV+/Not intubated	0.78 5	0.547 - 1.124	0.190
O-negative	ABO+Rh	COV+/Intubated vs COV+/Not intubated	0.65 4	0.158 - 2.042	0.616
O-positive	ABO+Rh	COV+/Intubated vs COV+/Not intubated	0.82 0	0.569 - 1.177	0.291
A	ABO	COV+/Died vs COV+/Alive	0.97 9	0.574 - 1.639	1.000

Blood group	Blood group type	Comparison groups	OR	95% CI	p-value
A-negative	ABO+Rh	COV+/Died vs COV+/Alive	0.46 4	0.011 - 3.067	0.708
A-positive	ABO+Rh	COV+/Died vs COV+/Alive	1.04 4	0.608 - 1.757	0.898
AB	ABO	COV+/Died vs COV+/Alive	2.43 7	0.679 - 7.226	0.088
AB-positive	ABO+Rh	COV+/Died vs COV+/Alive	2.43 7	0.679 - 7.226	0.088
B	ABO	COV+/Died vs COV+/Alive	0.84 5	0.402 - 1.646	0.751
B-negative	ABO+Rh	COV+/Died vs COV+/Alive	0.00 0	0 - 5.26	1.000
B-positive	ABO+Rh	COV+/Died vs COV+/Alive	0.91 9	0.436 - 1.794	0.872
O	ABO	COV+/Died vs COV+/Alive	0.96 6	0.586 - 1.585	0.906
O-negative	ABO+Rh	COV+/Died vs COV+/Alive	0.00 0	0 - 1.429	0.158
O-positive	ABO+Rh	COV+/Died vs COV+/Alive	1.11 3	0.675 - 1.827	0.718

Table 7: Distributions of blood groups between New York City data from the NYP EHR system and individuals from Shenzhen (cases from Shenzhen Third People's Hospital, controls from Shenzhen general population) and Wuhan (cases from Wuhan Jinyintan Hospital and Renmin Hospital of Wuhan University, controls from Wuhan general population). Shenzhen and Wuhan data reported by Zhao et al. [3].

Blood group	NYP general population	NYP COV+	Shenzhen general population	Shenzhen COV+	Wuhan general population	Wuhan Jinyintan COV+	Wuhan Renmin COV+
A	32.7% (35643)	34.2% (233)	28.8% (6728)	28.8% (82)	32.2% (1188)	37.7% (670)	39.8% (45)
AB	4.2% (4582)	3.1% (21)	7.3% (1712)	13.7% (39)	9.1% (336)	10% (178)	13.3% (15)
B	14.9% (16229)	17% (116)	25.1% (5880)	29.1% (83)	24.9% (920)	26.4% (469)	22.1% (25)
O	48.1% (52406)	45.7% (312)	38.8% (9066)	28.4% (81)	33.8% (1250)	25.8% (458)	24.8% (28)

Table 8: Weights for sites in random-effects meta-analyses conducted for each ABO blood group. Each blood group was compared against all others using data from NYP, and Zhao et al. (Wuhan Jinyintan, Renmin Hospital in Wuhan, and Shenzhen Third People's Hospital).

Blood group	Site	OR	95% CI	%Weight
A	NYP	1.0660	0.9095 - 1.2494	31.8
A	Wuhan Jinyintan	1.2790	1.1364 - 1.4395	39.3
A	Wuhan Renmin	1.3959	0.9519 - 2.0472	10.3
A	Shenzhen	1.0001	0.7727 - 1.2945	18.6

Blood group	Site	OR	95% CI	%Weight
B	NYP	1.1698	0.9573 - 1.4294	23.7
B	Wuhan Jinyintan	1.0828	0.9516 - 1.2321	57.1
B	Wuhan Renmin	0.8566	0.5460 - 1.3440	4.7
B	Shenzhen	1.2233	0.9458 - 1.5822	14.4
AB	NYP	0.7230	0.4678 - 1.1176	23.5
AB	Wuhan Jinyintan	1.1139	0.9201 - 1.3487	30.2
AB	Wuhan Renmin	1.5297	0.8783 - 2.6643	20.0
AB	Shenzhen	2.0071	1.4266 - 2.8237	26.3
O	NYP	0.9084	0.7810 - 1.0566	31.1
O	Wuhan Jinyintan	0.6799	0.5993 - 0.7715	32.9
O	Wuhan Renmin	0.6441	0.4179 - 0.9925	13.2
O	Shenzhen	0.6272	0.4842 - 0.8124	22.8

Table 9: Heterogeneity across meta-analysis sites.

Blood group	I-squared	I-squared 95% CI	Q	Q d.f.
A	47.1%	0.0 - 82.4	5.67	3
B	0.0%	0.0 - 79.4	2.23	3
AB	80.6%	48.9 - 92.6	15.43	3
O	72.1%	21.0 - 90.2	10.76	3

References

1. **Coronavirus disease 2019 (COVID-19) Situation Report – 76**
World Health Organization
WHO Coronavirus disease 2019 situation reports (2020-04-05) https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_2
2. **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study**
Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu, ... Bin Cao
The Lancet (2020-03) <https://doi.org/ggnxb3>
DOI: [10.1016/s0140-6736\(20\)30566-3](https://doi.org/10.1016/s0140-6736(20)30566-3)
3. **Relationship between the ABO Blood Group and the COVID-19 Susceptibility**
Jiao Zhao, Yan Yang, Hanping Huang, Dong Li, Dongfeng Gu, Xiangfeng Lu, Zheng Zhang, Lei Liu, Ting Liu, Yukun Liu, ... Peng George Wang
medRxiv (2020-03-27) <https://doi.org/ggpn3d>
DOI: [10.1101/2020.03.11.20031096](https://doi.org/10.1101/2020.03.11.20031096)
4. **ABO Blood Group and Susceptibility to Severe Acute Respiratory Syndrome**
JAMA
(2005-03-23) <https://doi.org/ftkw6v>
DOI: [10.1001/jama.293.12.1450-c](https://doi.org/10.1001/jama.293.12.1450-c) · PMID: [15784866](https://pubmed.ncbi.nlm.nih.gov/15784866/)
5. **ABO Blood Group Phenotypes and Plasmodium falciparum Malaria: Unlocking a Pivotal Mechanism**
María-Paz Loscertales, Stephen Owens, James O'Donnell, James Bunn, Xavier Bosch-Capblanch, Bernard J. Brabin
Advances in Parasitology (2007) <https://doi.org/db42m2>
DOI: [10.1016/s0065-308x\(07\)65001-5](https://doi.org/10.1016/s0065-308x(07)65001-5)
6. **Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens**
T Boren, P Falk, K. Roth, G Larson, S Normark
Science (1993-12-17) <https://doi.org/d3wbh6>
DOI: [10.1126/science.8018146](https://doi.org/10.1126/science.8018146) · PMID: [8018146](https://pubmed.ncbi.nlm.nih.gov/8018146/)
7. **Human susceptibility and resistance to Norwalk virus infection**
Lisa Lindesmith, Christine Moe, Severine Marionneau, Nathalie Ruvoen, Xi Jiang, Lauren Lindblad, Paul Stewart, Jacques LePendou, Ralph Baric
Nature Medicine (2003-04-14) <https://doi.org/c7xvwh>
DOI: [10.1038/nm860](https://doi.org/10.1038/nm860) · PMID: [12692541](https://pubmed.ncbi.nlm.nih.gov/12692541/)
8. **ABO blood group, hepatitis B viral infection and risk of pancreatic cancer**
De-Shen Wang, Dong-Liang Chen, Chao Ren, Zhi-Qiang Wang, Miao-Zhen Qiu, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
International Journal of Cancer (2012-07-15) <https://doi.org/cpfxbm>
DOI: [10.1002/ijc.26376](https://doi.org/10.1002/ijc.26376) · PMID: [21858814](https://pubmed.ncbi.nlm.nih.gov/21858814/)
9. **Relation of Infection with Neisseria gonorrhoeae to ABO Blood Groups**
M. T. Foster, A. H. Labrum

Journal of Infectious Diseases (1976-02-01) <https://doi.org/dt9x9d>
DOI: [10.1093/infdis/133.3.329](https://doi.org/10.1093/infdis/133.3.329) · PMID: [1254989](https://pubmed.ncbi.nlm.nih.gov/1254989/)

10. **COVID-19: Data - NYC Health** <https://www1.nyc.gov/site/doh/covid/covid-19-data.page>

11. **Meta-Analysis with R**

Guido Schwarzer, James R. Carpenter, Gerta Rücker

Use R! (2015) <https://doi.org/drbb>

DOI: [10.1007/978-3-319-21416-0](https://doi.org/10.1007/978-3-319-21416-0)

12. **Open collaborative writing with Manubot**

Daniel S. Himmelstein, Vincent Rubinetti, David R. Slochower, Dongbo Hu, Venkat S. Malladi, Casey S. Greene, Anthony Gitter

PLOS Computational Biology (2019-06-24) <https://doi.org/c7np>

DOI: [10.1371/journal.pcbi.1007128](https://doi.org/10.1371/journal.pcbi.1007128) · PMID: [31233491](https://pubmed.ncbi.nlm.nih.gov/31233491/) · PMCID: [PMC6611653](https://pubmed.ncbi.nlm.nih.gov/PMC6611653/)

13. **Frequencies and ethnic distribution of ABO and RhD blood groups in China: a population-based cross-sectional study**

Jue Liu, Shikun Zhang, Qiaomei Wang, Haiping Shen, Yiping Zhang, Min Liu

BMJ Open (2017-12-03) <https://doi.org/gcnrk5>

DOI: [10.1136/bmjopen-2017-018476](https://doi.org/10.1136/bmjopen-2017-018476) · PMID: [29203504](https://pubmed.ncbi.nlm.nih.gov/29203504/) · PMCID: [PMC5736034](https://pubmed.ncbi.nlm.nih.gov/PMC5736034/)

14. **ABO and Rh(D) phenotype frequencies of different racial/ ethnic groups in the United States**

George Garratty, Simone A. Glynn, Robin McEntire, Retrovirus Epidemiology Donor Study

Transfusion (2004-05) <https://doi.org/dkshr5>

DOI: [10.1111/j.1537-2995.2004.03338.x](https://doi.org/10.1111/j.1537-2995.2004.03338.x) · PMID: [15104651](https://pubmed.ncbi.nlm.nih.gov/15104651/)